Story perspectives

AbbVie’s Sales Surge Amid Mixed Analyst Ratings

1/31/2025

50 5

Summary

AbbVie Sales Outlook

AbbVie Inc. received mixed analyst ratings; TD Cowen raised its price target to $225, while Daiwa America downgraded to "hold."
The company anticipates over $31 billion in sales from immunology drugs Skyrizi and Rinvoq by 2027.
AbbVie reported $15.1 billion in sales, driven by Skyrizi and Rinvoq, despite declining Humira sales.
Analysts classify AbbVie as a "Moderate Buy," with an average target price of $205.

Summary

Investors Adjust AbbVie Holdings

Patton Fund Management acquired 28,466 shares of AbbVie for $5.1 million in Q4.
Sivik Global Healthcare's purchase of 25,000 shares positions AbbVie as its 19th largest holding.
OLD National Bancorp reduced its stake by 6%, now holding 134,248 shares valued at $23.9 million.
Cibc World Market increased its holdings by 23.7%, owning 591,531 shares worth $105.1 million.
AbbVie shares are trading at $175.54, with a market cap of $310.21 billion and a PE ratio of 60.95.

History

Historical Context

AbbVie’s current mixed analyst ratings reflect a historical trend of pharmaceutical companies facing market pressures post-blockbuster drugs. Similar to Pfizer's struggles after Lipitor's patent expiration, AbbVie must navigate declining Humira sales while banking on newer products like Skyrizi and Rinvoq to sustain growth.

1 of 3

AbbVie Sales Outlook

AbbVie Inc. received mixed analyst ratings; TD Cowen raised its price target to $225, while Daiwa America downgraded to "hold."
The company anticipates over $31 billion in sales from immunology drugs Skyrizi and Rinvoq by 2027.
AbbVie reported $15.1 billion in sales, driven by Skyrizi and Rinvoq, despite declining Humira sales.
Analysts classify AbbVie as a "Moderate Buy," with an average target price of $205.

1 / 3